【Abstract】 Objective To evaluate the therapeutic effects of hybrid bioartificial liver (HBL) on animal acute hepatic failure model. Methods HBL consisted of plasma exchange, hemofiltration and porcine hepatocyte-based bioartificial liver. Six experimental minipigs were induced to have acute hepatic failure by administration of D-galactosamine. After 48 hours the animals were treated with plasma exchange plus hemofiltration then followed by porcine hepatocyte-based bioartificial liver. Clinical manifestations and serum indexes of the animals were observed and compared with those at different treatment stages. Results No significant changes in vital signs were found, and the adverse effects did not occur in these animals during the treatment. Compared with those before HBL treatment, the concentrations of blood total bilirubin, NH3, alanine transferase, endotoxin and creatinine were much lower (P>0.01), and levels of fibrinogen, prothrombin activity and alpha-fetoprotein were much higher (P＜0.01) after HBL treatment. Compared with those after plasma exchange plus hemofiltration, serum fibrinogen and prothrombin activity were higher (P＜0.05), and serum NH3 and total bilirubin were lower after the porcine hepatocyte-based bioartificial liver treatment. Conclusions The treatment of HBL for acute hepatic failure is safe and effective, and is superior to the efficacy of plasma exchange plus hemofiltration.